Fiche centre
Fakultni nemocnice Hradec Kralove
Hradec Králové — Czechia
Essais liés15clinical trials
VilleHradec Královélocalisation
PaysCzechialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05660967
Essais cliniques associés
15| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Low Dose PF-07328948 | Insuffisance cardiaque | Phase 2 | NCT06991257 | A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | RECRUITING |
| BMS-986504 | Cancer | Phase 2/3 | NCT07063745 | MountainTAP-29 — A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | RECRUITING |
| Epcoritamab | SEP | Phase 2 | NCT05660967 | EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | TERMINATED |
| BIIB017 (peginterferon beta-1a) | SEP | Phase 3 | NCT03958877 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Tacabrutideg | Cancer | Phase 3 | NCT06846671 | CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | RECRUITING |
| Sonrotoclax | Cancer | Phase 3 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | RECRUITING |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| BMS-986368 | Myopathies | Phase 2 | NCT06782490 | MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01247324 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Cromolyn Sodium (34.2 mg BID) | Sclérose latérale amyotrophique | Phase 2 | NCT07142291 | PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Orelabrutinib | SEP | Phase 3 | NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | RECRUITING |
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 2 | NCT05119569 | FENopta — A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |